M.D., Ph.D. Managing Director,
United States Minor Outlying Islands
Jeffrey Bird, M.D., Ph.D., is a managing director at Sutter Hill Ventures, where he focuses on healthcare, including biotechnology and medical devices. In addition to Portola, he is currently a board member at AkaRx, Inc. (cancer and hematology therapeutics), Macusight (ophthalmic therapeutics), NuGen Technologies (research reagents), Restoration Robotics (aesthetic surgery devices), Roxro Pharma (pain therapeutics) and Xoft Microtube (cancer radiation devices). He also represents the firm’s investments in Acceleron Pharmaceuticals (metabolic therapeutics) and Barrx (gastrointestinal devices).
Dr. Bird was previously senior vice president, business operations at Gilead Sciences, where he worked from 1988 to 1990 and then from 1992 to 2000. He received his B.S. from Stanford, a Ph.D. in cancer biology and an M.D. from Stanford Medical School.